Online Appendix Table A1- Number of patients with HbA1c and FPG data at randomization and month 4

|                | All Patients |                     |                     | No Diabetes |                     |                     | Diabetes |                     |
|----------------|--------------|----------------------|----------------------|-------------|----------------------|----------------------|----------|----------------------|
|                | Placebo      | Ranolazine           | Placebo              | Ranolazine  | Placebo              | Ranolazine           | Placebo  | Ranolazine           |
|                | (n=2679)     | (n=2565)             | (n=1787)             | (n=1723)    | (n=892)              | (n=842)             |          |                      |
| HbA1c n (%)    | 2198 (82%)   | 2108 (82%)           | 1428 (80%)           | 1401 (81%)  | 770 (86%)            | 707 (84%)           |          |                      |
| FPG n (%)      | 932 (35%)    | 922 (36%)            | 604 (34%)            | 612 (36%)   | 328 (37%)            | 310 (37%)           |          |                      |

Online Appendix Table A2- Effect of ranolazine between month 0 and 4 for patients without a history of DM and possible new or undiagnosed DM

Patients with possible new DM at randomization (FPG≥126-400)

|                | FPG Month 0 | Change in FPG 0 to month 4 |
|----------------|-------------|-----------------------------|
|                | (mg/dl)     | (mg/dl)                     |
| Placebo        | 148.0 (95%CI: 140.5, 155.6, n=60) | -44.2 (95%CI: -53.8, -34.6, n=60) |
| Ranolazine     | 151.7 (95%CI: 143.5, 159.9, n=68)  | -48.1 (95%CI: -56.7, -39.5, n=68)  |
|                |             | *p=0.523                    |

Patients with possible new DM at randomization (HbA1c ≥6.5-10%)

|                | HbA1c Month 0 | Change in HbA1c 0 to month 4 |
|----------------|--------------|-----------------------------|
|                | (%)          | (%)                         |
| Placebo        | 7.3 (95%CI: 7.2, 7.4, n=185) | -0.54 (95%CI: -0.74, -0.34, n=185) |
| Ranolazine     | 7.2 (95%CI: 7.1, 7.4, n=178)  | -0.93 (95%CI: -1.12, -0.73, n=178)  |
|                | Δ -0.39%     | *p=0.007                    |

*Paired t-test  
Mean, 95% Confidence interval and n

Online Appendix Table A3- HbA1c at randomization for patients with diabetes subgrouped by treatment for diabetes

|                | Placebo | Ranolazine |
|----------------|---------|------------|
| Patients with diabetes n (%) HbA1c (%) | 770 7.4 (7.2,7.5) | 707 7.5 (7.3,7.6) |
| Subgroups      | Placebo | Ranolazine |
| No anti-diabetic drugs n (%) HbA1c (%) | 128 (16.6%) 6.4 (6.2,6.7) | 134 (19.0%) 6.5 (6.2,6.8) |
| OHA n (%) HbA1c (%) | 425 (55.2%) 7.4 (7.2,7.6) | 380 (53.7%) 7.4 (7.3,7.6) |
| Insulin +/- OHA n (%) HbA1c (%) | 217 (28.2%) 7.9 (7.7,8.2) | 193 (27.3%) 8.2 (7.9,8.5) |

All patients had HbA1c values at 0 and 4 months  
Mean HbA1c % (95% Confidence Interval)  
OHA- Oral hypoglycemic agents
(A). The placebo-adjusted effect of ranolazine on HbA1c in patients with hyperglycemia (HbA1c ≥ 8-10% at randomization) and a history of angina was -0.5% (95%CI: -0.9 to -0.1, p=0.014) and -0.8% (95%CI: -1.2 to -0.3, p<0.001) for patients with no history of angina. The placebo corrected effect of ranolazine on HbA1c was independent of a history of angina (p=0.213). The absolute HbA1c reduction in ranolazine treated patients with and without angina was 1.1% (95%CI: -1.4 to -0.9) and 1.2% (95%CI: -1.5 to -0.9) respectively. (B.) The placebo-adjusted effect of ranolazine on FPG in hyperglycemic patients (FPG ≥ 150-400 mg/dl at randomization) with a history of angina was -26.2 mg/dl (95%CI: -48.2 to -4.3, p=0.020) and -25.1 mg/dl (95%CI: -49.5 to -0.7, p=0.044) for patients with no history of angina. The placebo corrected effect of ranolazine on FPG was independent of a history of angina (p=0.408). The absolute FPG reduction in ranolazine treated patients with and without angina was -59.2 mg/dl (95%CI: -75.9 to -42.4) and -59.6 mg/dl (95%CI: -75.8 to -59.6) respectively. Changes in HbA1c and FPG at month 4 are summarized by mean, associated 95%CI and number of patients (n).
Online Appendix Figure 2- Change in HbA1c from month 0 to 4 for patients with a history of DM by major concomitant hypoglycemic agent(s).

The placebo-adjusted effect of ranolazine on HbA1c for patients with DM and an HbA1c at randomization of ≥6-10% by major concomitant hypoglycemic agent were as follows: No DM drug -0.24% (95%CI: -0.54, 0.07, p=0.13); sulphonlurea only -0.40%, (95%CI: -0.72, -0.07, p=0.016); biguanide only (metformin) -0.44%, (95%CI: -0.84, -0.04, p=0.0326); sulphonlurea and biguanide -0.48%, (95%CI: -0.86, -0.11, p=0.012); insulin (any form) -0.46%, (95%CI: -0.86, -0.05, p=0.027). Changes in HbA1c and FPG at month 4 are summarized by mean, 95% confidence interval, p-value (paired t-test) and n.